| Literature DB >> 34236800 |
Marcin P Szczechowicz1, Alexander Weymann1, Sabreen Mkalaluh2, Ahmed Mashhour2, Konstantin Zhigalov1, Michel Pompeu B O Sá3, Alina Zubarevich1, Jerry Easo.
Abstract
INTRODUCTION: Destructive aortic root endocarditis is associated with high mortality rates. The objective of this article was to characterize the clinical and microbiological profiles of these patients, especially concerning an already implanted aortic valve prosthesis. We also focused on prognostic factors.Entities:
Keywords: Anti-Bacterial Agents; Coagulase; Delayed Diagnosis; Endocarditis, Bacterial; Incidence; Prognosis; Reinfection; Risk Factors
Mesh:
Year: 2021 PMID: 34236800 PMCID: PMC8597613 DOI: 10.21470/1678-9741-2020-0412
Source DB: PubMed Journal: Braz J Cardiovasc Surg ISSN: 0102-7638
Preoperative characteristics and comorbidities.
| Characteristics | Native valve endocarditis | Early-onset prosthetic valve endocarditis | Late-onset prosthetic valve endocarditis | |
|---|---|---|---|---|
| N | 31 (38.75%) | 8 (10%) | 41 (51.25%) | |
| Female | 3 (9.7%) | 0 | 8 (19.5%) | 0.269 |
| Age (years) | 55 (47 to 69) | 71.5 (62 to 74.8) | 66 (55 to 72) | 0.010 |
| Previous heart surgery | 3 (9.7%) | 8 (100%) | 41 (100%) | - |
| Aortic valve surgery | 0 | 8 (100%) | 41 (100%) | < 0.001 |
| Mechanical aortic valve prosthesis | 0 | 2 (25%) | 20 (48.8%) | < 0.001 |
| Biological aortic valve prosthesis | 0 | 6 (75%) | 21 (51.2%) | < 0.001 |
| Coronary artery bypass grafting | 0 | 0 | 10 (24.4%) | 0.004 |
| Time from prior aortic valve surgery to redo surgery for destructive endocarditis | - | 115 days (101 to 222) | 5.1 years (3.2 to 8.9) | < 0.001 |
| Relevant coronary artery disease | 4 (12.9%) | 1 (12.5%) | 11 (26.8%) | 0.293 |
Surgical data.
| Characteristics | Native valve endocarditis | Early-onset prosthetic valve endocarditis | Late-onset prosthetic valve endocarditis | |
|---|---|---|---|---|
| N | 31 (38.75%) | 8 (10%) | 41 (51.25%) | |
| Surgery time (min) | 209 (160 to 302) | 263 (218 to 438) | 303 (251 to 390) | 0.004 |
| Cardiopulmonary bypass time (min) | 127 (92 to 231) | 161 (135 to 293) | 195 (147 to 249) | 0.040 |
| Cross-clamping time (min) | 100 (71 to 135) | 118 (99 to 144) | 128 (102 to 148) | 0.065 |
| Periannular complications | ||||
| Fistula | 3 (9.7%) | 1 (12.5%) | 5 (12.2%) | 0.939 |
| Abscess | 13 (41.9%) | 2 (25%) | 22 (53.7%) | 0.274 |
| Aortoventricular dehiscence | 1 (3.2%) | 5 (62.5%) | 14 (34.1%) | < 0.001 |
| Type of implanted aortic root prosthesis | ||||
| Porcine aortic root xenograft | 22 (71%) | 6 (75%) | 25 (61%) | 0.727 |
| Biological valve conduit | 5 (16.1%) | 0 | 8 (19.5%) | |
| Mechanical valve conduit | 2 (6.5%) | 1 (12.5%) | 2 (4.9%) | |
| Homograft valve | 2 (6.5%) | 1 (12.5%) | 6 (14.6%) | |
| Concomitant procedures | 14 (45.2%) | 3 (37.5%) | 25 (61%) | 0.276 |
| Mitral valve replacement | 7 (22.6%) | 1 (12.5%) | 6 (14.6%) | 0.629 |
| Replacement of the ascending aorta | 2 (6.5%) | 2 (25%) | 11 (26.8%) | 0.080 |
| Coronary artery bypass grafting | 5 (16.1%) | 0 | 12 (29.3%) | 0.121 |
| Among them: bailout bypass | 3 (9.7%) | 0 | 6 (14.6%) | 0.458 |
Microbiological characteristics.
| Characteristics | Native valve endocarditis | Early-onset prosthetic valve endocarditis | Late-onset prosthetic valve endocarditis | |
|---|---|---|---|---|
| N | 31 (38.75%) | 8 (10%) | 41 (51.25%) | |
| 9 (29%) | 5 (62.5%) | 15 (36.6%) | 0.214 | |
| Methicillin-resistant | 3 (9.7%) | 2 (25%) | 5 (12.2%) | 0.504 |
|
| 1 (3.2%) | 0 | 7 (17.1%) | 0.093 |
| Coagulase-negative | 8 (25.8%) | 5 (62.5%) | 8 (19.5%) | 0.041 |
| 6 (19.4%) | 0 | 0 | 0.006 | |
|
| 1 (3.2%) | 1 (12.5%) | 9 (22%) | 0.073 |
| Another Gram-positive | 3 (9.7%) | 0 | 2 (4.9%) | 0.526 |
| Gram-negative | 1 (3.2%) | 0 | 0 | 0.449 |
|
| 0 | 0 | 1 (2.4%) | 0.618 |
| Unknown | 11 (35.5%) | 2 (25%) | 14 (34.1%) | 0.853 |
| Resistant microorganisms | 8 (25.8%) | 3 (37.5%) | 14 (34.15) | 0.693 |
| No antibiotics at admission | 5 (16.1%) | 3 (37.5%) | 6 (14.6%) | 0.288 |
| Antimicrobial monotherapy at admission | 10 (32.3%) | 1 (12.5%) | 9 (22%) | 0.419 |
Postoperative characteristics.
| Characteristics | Native valve endocarditis | Early-onset prosthetic valve endocarditis | Late-onset prosthetic valve endocarditis | |
|---|---|---|---|---|
| N | 31 (38.75%) | 8 (10%) | 41 (51.25%) | |
| Acute kidney injury | 3 (9.7%) | 2 (25%) | 11 (26.8%) | 0.184 |
| Resternotomy due to bleeding | 6 (19.4%) | 3 (37.5%) | 4 (9.8%) | 0.126 |
| Stroke | 0 | 0 | 2 (4.9%) | 0.377 |
| Respiratory failure | 5 (16.1%) | 4 (50%) | 13 (31.7%) | 0.110 |
| Low output syndrome | 2 (6.5%) | 2 (25%) | 4 (9.8%) | 0.296 |
| Pacemaker implantation | 2 (6.5%) | 1 (12.5%) | 5 (12.2%) | 0.702 |
| Packed red cells transfusion (ml) | 900 (600 to 2250) | 3900 (450 to 6975) | 1350 (600 to 3000) | 0.497 |
| Mechanical ventilation (hours) | 5 (2 to 39) | 147 (9 to 463) | 24 (3 to 84) | 0.045 |
| Intensive care unit length of stay (days) | 3 (1 to 6) | 7 (3 to 14) | 3 (2 to 9) | 0.569 |
| In-hospital length of stay (days) | 8 (6 to 17) | 10 (6 to 14) | 9 (7 to 14) | 0.826 |
| 30-day mortality | 3 (9.7%) | 3 (37.5%) | 16 (39%) | 0.018 |
Fig. 1Cumulative survival of all three analyzed groups. The survival profiles were compared with log-rank test, generally (P=0.044) and pairwise: native valve endocarditis (NVE) vs. early-onset prosthetic valve endocarditis (PVE) (P=0.008), NVE vs. late-onset PVE (P=0.039), and early- vs. late-onset PVE (P=0.499).
Fig. 2Cumulative freedom from composite endpoint (stroke, aortic valve reinfection, and aortic valve reoperation for any cause) within all three analyzed groups. Comparison with log-rank test, generally (P=0.024) and pairwise: native valve endocarditis (NVE) vs. early-onset prosthetic valve endocarditis (PVE) (P=0.008), NVE vs. late-onset PVE (P=0.013), and late- vs. early-onset PVE (P=0.133).
Independent risk factors of mortality
| Characteristics | 30-day mortality - univariate logistic regression | Long-term mortality - univariate proportional hazard regression | ||
|---|---|---|---|---|
| Odds ratio with 95% confidence interval | Hazard ratio with 95% confidence interval | |||
| Age (years) | 1.03 (0.00 to 1.07) | 0.143 | 1.02 (0.99 to 1.05) | 0.153 |
| History of cardiac surgery | 4.8 (1.3 to 18.0) | 0.020 | 1.5 (0.7 to 3) | 0.289 |
| History of aortic valve surgery | 5.1 (1.4 to 19.3) | 0.015 | 1.6 (0.8 to 3.2) | 0.206 |
| PVE | 5.9 (1.6 to 22.0) | 0.008 | 1.9 (0.9 to 3.9) | 0.083 |
| Fistula | 4.0 (0.96 to 16.5) | 0.058 | 2.2 (0.9 to 5.4) | 0.079 |
| Abscess | 0.96 (0.36 to 2.6) | 0.930 | 0.8 (0.4 to 1.6) | 0.571 |
| Aortoventricular dehiscence | 5.4 (1.8 to 16.3) | 0.002 | 2.4 (1.2 to 4.7) | 0.014 |
| Concomitant coronary artery bypass grafting | 8.7 (2.6 to 28.4) | <0.001 | 3.8 (1.8 to 7.8) | <0.001 |
| Bailout bypass surgery | 13.1 (2.5 to 69.0) | 0.003 | 4.3 (1.9 to 9.9) | <0.001 |
| Unknown microorganism | 0.9 (0.3 to 2.5) | 0.822 | 0.9 (0.5 to 1.9) | 0.866 |
| Resistant microorganisms | 0.8 (0.3 to 2.3) | 0.637 | 1.1 (0.5 to 2.2) | 0.871 |
| No antibiotics at admission | 5.0 (1.5 to 16.6) | 0.010 | 2 (0.9 to 4.4) | 0.086 |
PVE=prosthetic valve endocarditis
| Abbreviations, acronyms & symbols | |
|---|---|
| BCNIE | = Blood culture-negative IE |
| CABG | = Coronary artery bypass grafting |
| CI | = Confidence intervals |
| CoNS | = Coagulase-negative Staphylococci |
| CPB | = Cardiopulmonary bypass |
| ECMO | = Extracorporeal membrane oxygenation |
| FFCE | = Freedom from the composite endpoint |
| HACEK | = Hemophilus spp., Aggregatibacter actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens, and Kingella kingae |
| HR | = Hazard ratios |
| IE | = Infective endocarditis |
| NVE | = Native valve endocarditis |
| OR | = Odds ratios |
| PVE | = Prosthetic valve endocarditis |
| Authors' roles & responsibilities | |
|---|---|
| MPS | Substantial contributions to the conception or design of the work; and the acquisition, or analysis of data for the work; drafting the work; final approval of the version to be published |
| AW | Substantial contributions to the conception of the work; revising the work critically for important intellectual content; final approval of the version to be published |
| SM | Substantial contributions to the design of the work; final approval of the version to be published |
| AM | Substantial contributions to the design of the work; and analysis of data for the work; final approval of the version to be published |
| KZ | Substantial contributions to the acquisition and analysis of data for the work; final approval of the version to be published |
| MPBOS | Revising the work critically for important intellectual content; final approval of the version to be published |
| AZ | Substantial contributions to the design of the work; and acquisition of data for the work; revising the work critically for important intellectual content; final approval of the version to be published |
| JE | Substantial contributions to the conception of the work; and analysis of data for the work; drafting the work; final approval of the version to be published |